Information Provided By:
Fly News Breaks for May 11, 2018
LJPC
May 11, 2018 | 07:13 EDT
H.C. Wainwright analyst Edward White lowered his price target for La Jolla Pharmaceutical to $72 after the company announced a $125M royalty financing agreement with HealthCare Royalty Partners. The analyst, however, thinks the deal should give investors more confidence in Giapreza's success. He keeps a Buy rating on La Jolla.
News For LJPC From the Last 2 Days
There are no results for your query LJPC